Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Pacira Pharmaceuticals (NASDAQ: PCRX) shares are down 15% at 12:00 p.m. EDT today following word that its pain medicine Exparel didn't perform as well as hoped in key phase 3 studies.
Pacira Pharmaceuticals already markets the surgical-pain medicine Exparel, and its sales have been growing quickly as doctors embrace ways to control pain that may reduce a patient's need for rescue pain medications, like opioids.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Pacira Pharmaceuticals Aktie
11,40 €
-1,72 %
Die Community bevorzugt Pacira Pharmaceuticals, mit deutlich mehr Buy- (22) als Sell-Einschätzungen (1).
Ein Kursziel von 41 € für Pacira Pharmaceuticals würde den aktuellen Kurs von 11.4 € signifikant übertreffen.
